⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GILD News
Gilead Sciences Inc
AI Supercomputing Platform Market Research 2026-2032: Competition Intensifies as NVIDIA Leads While AMD, Intel and Hyperscalers Expand Custom Silicon Strategies
globenewswire.com
NVDA
AMD
INTC
HPE
DELL
MSFT
AMZN
GOOG
ORCL
SMCI
MU
META
TSM
BRO
CSCO
IBM
ARM
AMAT
LRCX
KLAC
QCOM
CRSP
REGN
GILD
BMY
MRNA
BIIB
EXAS
ILMN
VRTX
AZN
PFE
JNJ
AMGN
LLY
ABBV
BKR
XOM
CVX
NEE
DUK
SO
ED
PCG
SRE
AEP
WEC
ETR
NI
XEL
NRG
CEG
EIX
FE
D
CMS
PNW
ES
$9.5+ Bn ADC Technology Market Industry Trends and Global Forecasts to 2040 - More Than 50% of the Technology Providers Have Signed Multiple Partnerships to Out-license Their Technologies
globenewswire.com
TMDX
GILD
AZN
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
businesswire.com
GILD
7MM Human Immunodeficiency Virus (HIV) Drug Forecast and Market Analysis Report 2026: Pipeline STRs Will Not Surpass Biktarvy in Terms of Commercial Success - Outlook to 2033
globenewswire.com
GILD
GSK
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
accessnewswire.com
NNVC
GILD
Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight
globenewswire.com
AZN
ABBV
GILD
BMY
FDA Grants Accelerated Approval to Gilead’s Hepcludex ® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
businesswire.com
GILD
Gilead Receives CHMP Positive Opinion for Trodelvy ® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
businesswire.com
GILD
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
businesswire.com
GILD
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
globenewswire.com
SNGX
IPHA
BMY
NKTX
AZN
MRK
TAK
NVS
GMAB
ABBV
BIIB
CRSP
INCY
ALKS
PFE
REGN
GILD
AMGN